

# Subject Index, 1984

## Vol. 34, Nos. 1-6

### A

**ACR Patterns of Care Study**, 75-85, 303  
Status of radiation treatment in the US, 75-85, 303  
Background and methods, 76-79, 303  
Future surveys, 84  
Outcome for certain sites, 80-84  
Study criteria, 79-80

#### Actinomycin D, 4

**Adenomas, colorectal**, 167-176  
Classification of, 167-175  
Detection of, 159  
And endocavitary irradiation, 336  
Malignant potential, 167-175  
Management of patients with, 167-175  
Recurring and synchronous lesions, 168, 170-171, 174-175  
Polypectomy, 167-175

#### Adrenal tumors

A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93-106

#### Adriamycin (doxorubicin, hydroxydaunorubicin), 3-4, 274, 277, 296

#### Alcohol

Abuse combined with cigarette smoking, increased cancer incidence, 123

#### Arteriography

Use in locating pheochromocytomas, 90

#### Asbestos, 44-56

Death rates of asbestos workers, 50-53

#### Exposure and neoplasia (classic), 48-56

Gastrointestinal cancer in asbestos workers, 54-55  
Historical perspective (classic), 44-47  
Smoking habits of asbestos workers, 52-54

#### Atrial metastasis (case report), 40-43

### B

#### Bladder cancer

Death rates for, 13, 15  
Incidence of, 14  
Mortality rates for, 9  
Sexual rehabilitation, 71-72  
And urostomy appliance, 71  
Survival rates for, 20-21, 23, 283-284, 287, 289, 291

#### Bleomycin, 3, 119

#### Bone cancer

Death rates for, 15  
Incidence of, 14, 22  
Mortality rates for, 9  
Survival rates for, 287

#### Brain and central nervous system cancer

Death rates for, 15  
Incidence of, 14, 21-22  
Mortality rates for, 9  
Survival rates for, 23, 287

#### Breast cancer, 345-351

Death rates for, 7, 12, 15, 17, 19  
Estrogen and, 215-216, 220, 222, 224-226  
Incidence of, 7, 14, 16, 21, 64 (letter), 346  
In obese people, 122

# Subject Index, 1984

## Vol. 34, Nos. 1-6

### A

**ACR Patterns of Care Study**, 75-85, 303  
Status of radiation treatment in the US, 75-85, 303  
Background and methods, 76-79, 303  
Future surveys, 84  
Outcome for certain sites, 80-84  
Study criteria, 79-80

#### Actinomycin D, 4

**Adenomas, colorectal**, 167-176  
Classification of, 167-175  
Detection of, 159  
And endocavitary irradiation, 336  
Malignant potential, 167-175  
Management of patients with, 167-175  
Recurring and synchronous lesions, 168, 170-171, 174-175  
Polypectomy, 167-175

#### Adrenal tumors

A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93-106

#### Adriamycin (doxorubicin, hydroxydaunorubicin), 3-4, 274, 277, 296

#### Alcohol

Abuse combined with cigarette smoking, increased cancer incidence, 123

#### Arteriography

Use in locating pheochromocytomas, 90

#### Asbestos, 44-56

Death rates of asbestos workers, 50-53

#### Exposure and neoplasia (classic), 48-56

Gastrointestinal cancer in asbestos workers, 54-55  
Historical perspective (classic), 44-47  
Smoking habits of asbestos workers, 52-54

#### Atrial metastasis (case report), 40-43

### B

#### Bladder cancer

Death rates for, 13, 15  
Incidence of, 14  
Mortality rates for, 9  
Sexual rehabilitation, 71-72  
And urostomy appliance, 71  
Survival rates for, 20-21, 23, 283-284, 287, 289, 291

#### Bleomycin, 3, 119

#### Bone cancer

Death rates for, 15  
Incidence of, 14, 22  
Mortality rates for, 9  
Survival rates for, 287

#### Brain and central nervous system cancer

Death rates for, 15  
Incidence of, 14, 21-22  
Mortality rates for, 9  
Survival rates for, 23, 287

#### Breast cancer, 345-351

Death rates for, 7, 12, 15, 17, 19  
Estrogen and, 215-216, 220, 222, 224-226  
Incidence of, 7, 14, 16, 21, 64 (letter), 346  
In obese people, 122

In people with diets high in fat, 122

Mammography, 57-59, 64 (letter)

Breast Cancer Detection

Demonstration Projects, 57-58

Mastectomy (Halsted radical), 346

Mortality rates for, 9

Screening for, 344

Survival rates for, 20, 23, 283-284, 287-289, 291

**Butyrophenones**, 5

---

**C**

**Cancer, classification and staging of**

Request for suggestions on a unified system for, 304

**Cancer, nutrition and**, 121-126

**Cancer control**, 328-332, 340-344

Definition of, 329, 340

Interrelationship in the community of clinical research and, 340-344

Clinical Oncology Program (COP), 343

Community Clinical Oncology Program (CCOP), 340, 343, 346-347

Community Hospital Oncology Program (CHOP), 343

Existing model of, 340-341

Goal of, 340

New model of, 340, 342

Scientific approach to, 328-332

Concept development and implementation, 328-329

Phases of research process, 329-331

**Cancer mortality among Mormons**, 128

Notice to readers, 128

**Cancer patients' attitudes toward hospice**, 191-201

**Cancer prevention**, 121-126

ACS nutritional recommendations, 121-126

**Cannabinoids**, 5, but see correction for nabilone dosage, page 147

**Case reports**, 40-43, 110-117, 295-298

Neurofibrosarcoma and the sign of Leser-Trelat, 295-298

Primary cardiac osteosarcoma: multidisciplinary aspects applicable to extraskeletal osteosarcoma generally, 110-117

Secondary carcinoma involving the left atrium, 40-43

**Cervical cancer**, 306-327

Age distribution by stage, 292

Death rates for, 15

And DES, 226

Detection, epidemiology, diagnosis, and treatment of early lesions, 306-327

Colposcopy and biopsy techniques, 308-309, 312

Condylomas, 307, 314, 316

Epidemiology, 312-313

Herpes virus, 313-314

Papanicolaou smear, 307-308

Papilloma virus, 314-316

In pregnancy, 313

Pretreatment evaluation, 316-318

Screening techniques, 306-308

Staging of lesions, 316-318

Treatment of, 318-325

Types of lesions, 306-325

And estrogen, 226

Incidence of, 14

And smoking (letter), 302-303

Survival rates for, 20, 23, 283-284, 287-289, 291-293

Treatment of, 80-81

**Chemotherapy**, 2-6, 345-351

(See also, specific agents)

Is aggressive adjuvant chemotherapy the Halsted radical of the '80s?, 345-351

Cytotoxic vs endocrine therapy debate, 346

Nursing role in, 345

Quality vs quantity of life, 345

Risk of developing nonlymphocytic leukemia, 349

Side effects of treatment, 345-351

Duration of therapy, 3

Inappropriate medical strategies, 3

Long-term vs short-term effects of, 2

In lung cancer, 273-278

Multiple-agent approaches for alleviation of nausea and vomiting in, 5

And ethics of patient requests in experimental medicine, 118-120

Nausea and vomiting in, 2-6, 345

Mechanisms of, 4

Prevention of, 4-5

Need for research in, 3-5

In neurofibrosarcoma (case report), 295-297

In osteosarcoma, 116

Sites of action, 4

As symptomatic treatment, 188

**Churg, Jacob**, 45-46

Historical perspective of asbestos (classic), 45-47

**Cigarette smoking**  
And alcohol abuse, increased cancer incidence, 123  
Cancer death rates due to, 125  
And cervical cancer (letter), 302–303  
Decline in (letter), 128  
In the genesis of small cell carcinoma, 269–270  
Smoking habits of asbestos workers, 52–54

**Circumcision**  
And penile cancer, correction (letter), 238

**Cisplatin**, 3–5, 119, 277–278, 296

**Classics in oncology**, 44–56, 93–106, 282–294  
Asbestos exposure and neoplasia, 48–56  
Asbestos: historical perspective, 44–47  
A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis, 93–106  
Survival in untreated and treated cancer, 282–294

**Clinical research**, 340–344  
Interrelationship in the community of cancer control and, 340–344

**CMF**, 346

**Colonoscopy**  
For colorectal cancer detection, 151–155, 160, 167  
In endocavitary irradiation for adenocarcinoma of the rectum, 333–339  
As follow-up in patients with colorectal adenomas, 170–175

**Colorectal cancer**, 130–176, 333–339  
Death rates for, 7, 12–13, 15, 17–18, 48, 52  
Endocavitary irradiation for adenocarcinoma of the rectum, 333–339  
Advantages of, 339  
As an alternative to surgery, 333–339  
Detection methods, 333  
Method of treatment, 334–335  
As palliation, 335–336  
Precautions, 336–339  
Selecting suitable patients for, 333–334  
Incidence of, 7, 14, 16, 21, 122, 131–132, 149, 158  
Mortality rates for, 9  
Survival rates for, 20, 23, 158–159, 162, 283–284, 287–289, 291, 293

**Third International Symposium on,**  
130–176  
Colonoscopy, 151–155, 160  
Endoscopy, 151–155  
Fecal occult blood test, 131–132, 134–137  
Management of patients with colorectal adenomas, 167–176  
Proctosigmoidoscopy, 132, 151, 153–155, 158–166  
Screening for, 132–134, 158–160

**Colposcopy**  
For cervical cancer detection, 308–312

**Computed tomography**  
In esophageal cancer (letter), 127  
In locating pheochromocytomas, 90–91  
In osteosarcoma, 116

**Condylomas**  
In cervical cancer, 307, 314, 316

**Connective tissue cancer**  
Death rates for, 15  
Incidence of, 9, 14, 22  
Mortality rates for, 9

**Corrections**, 147, 201, 238, 303  
Author's correction (letter), 303  
Dosage for nabilone, 147, 201  
Penile cancer and circumcision (letter), 238

**Corticosteroids**, 5

**Cyclophosphamide**, 3, 274, 277, 296

**Cystectomy**, 71–72  
Sexual rehabilitation and, 71–72

**Cytotoxic agents**, 345–351

---

**D**

**Dimethyl triazeno imidazole carboxamide (DTIC)**, 4

**Disseminated cancer**, 356–357 (letter)

**Doxorubicin** (See Adriamycin)

---

**E**

**Endometrial cancer**, 210–231  
Estrogen and, 210–231

**Endoscopy**  
In colorectal adenomas, 168–170, 172–173  
For colorectal cancer detection, 151–155  
In esophageal cancer (letter), 127  
As follow-up in patients with colorectal cancer, 170–175

**Esophageal cancer**  
Computed tomography in (letter), 127–128  
Death rates for, 13, 15  
Endoscopy in (letter), 127  
Incidence of, 14, 21  
In alcohol abusers who smoke cigarettes, 123  
In people with diets high in nitrate and nitrite, 123  
In people with diets high in vitamins A and C, 123  
Roentgenography in (letter), 127  
Survival rates for, 23, 283, 287, 291

**Esthesioneuroblastoma, 356**  
(letter)

**Estrogen, 210–231**  
Administration to menopausal women (opinions), 210–231  
Benefits, 210–211  
Risks, 211–216, 220–229  
Endometrial cancer and, 211–215, 220–229  
Other types of tumors, 226–228  
Recommendations for, 216

**Ethics**  
Patient requests in experimental medicine, 118–120

**Etoposide, 274, 278**

**Experimental medicine**  
Ethics of patient requests in (opinion), 118–120  
National Commission for the Protection of Human Subjects, 118

**Eye cancer**  
Death rates for, 15  
Incidence of, 14, 22

**F**

**Fecal occult blood test, 134–157**  
For colorectal cancer detection, 131, 132, 134–157, 172–174  
Diagnostic evaluation of positive test, 148–157

**Guidelines, 154–155**  
Results of clinical trials, 154

**Diet (letter), 352–353**  
Factors that affect the test, 135–139  
Guidelines for administration of, 134–147  
Improving test performance, 139–142  
Screening results, 142–145

**Feedback, 64, 127–128, 238–240, 299–303, 352–357**  
Author's correction, 303  
Cancer and pregnancy, 238–240  
Decline in smoking, 128  
Esophageal cancer, 127–128  
Esthesioneuroblastoma, 356  
Fecal occult blood test, 352–353  
Growth of disseminated cancer, 356–357  
Immuno-augmentative therapy, 356  
Malignant melanoma, 353–354  
Mammography, 64  
Penile cancer and circumcision, correction, 238  
Sexual rehabilitation, 354–355  
Smoking and cervical cancer, 302–303  
Thyroid cancer, 299–302

**5-Fluorouracil, 119**

**Floxuridine, 3–4**

**G**

**Gallbladder cancer**  
Incidence of, 122  
In obese people, 122

**Gastrointestinal cancer**  
Incidence of, 54–55, 123  
In asbestos workers, 54–55  
In people with diets high in cruciferous vegetables, 123

**H**

**Hammond, E. Cuyler, 45–46**  
Historical perspective of asbestos (classic), 45–47

**Herpes virus**  
Transmissible agent of cervical cancer, 313–314

**Hodgkin's disease**  
Chemotherapy for, 3  
Death rates for, 15  
Incidence of, 14  
Mortality rates for, 9  
Survival rates for, 20, 23

Treatment of, 80-81  
Tribute to Henry S. Kaplan, 206-209

## Hospice, 178-205

Cancer patients' attitudes toward, 191-201  
According to gender, 195-197, 199  
Likelihood of using various programs, 193, 197  
Professional vs patient priorities, 195, 198  
Concept of, 202-203  
Incidence of in US, 191  
Nursing role in, 204-205  
An oncologist's viewpoint on, 178-182  
Problems of, 180-181  
Research on psychosocial aspects and control of symptoms, 181-182  
Special program features, 178-180  
Problems of, 183-190  
Appropriate care, 184-185  
Case studies, 185-188  
Chemotherapy as symptomatic treatment, 188  
Cost effectiveness, 189  
Identification of the dying process, 188-189

## Hydroxydaunorubicin (See Adriamycin)

## Hysterectomy

As preventive treatment in early cervical cancer, 319-320

## I

<sup>131</sup>I-Metaiodobenzylguanidine, 86-92  
In locating pheochromocytomas with scintigraphy, 86-92

**Immuno-augmentative therapy**  
(unproven methods), 232-237, 356

**Insurability and level I (*in situ*) melanoma**, 107-109, 353-354

## K

**Kaplan, Henry Seymour**, 206-209  
Contributions to radiology, 207-209  
Medical linear accelerator, 209  
Reflections on his life, 209  
Tributes to, 206-209  
Work on lymphomas and Hodgkin's disease, 207-209

## Kidney cancer

Death rates for, 15  
Incidence of, 14, 21-22

In obese people, 122  
Mortality rates for, 9  
Survival rates for, 20, 23, 289

## L

### Laryngeal cancer

Death rates for, 15  
Incidence of, 14  
In alcohol abusers who smoke cigarettes, 123  
In people with diets high in vitamin A, 123  
Survival rates for, 23, 35, 283, 287-289, 291  
Treatment of, 81-83

### Leser-Trélat, sign of

And neurofibrosarcoma (case report), 295-298

### Leukemia

Death rates for, 7, 12-13, 15, 17, 19  
Incidence of, 7, 14, 16, 22  
Mortality rates for, 9  
Resulting from cytotoxic chemotherapy, 349  
Survival rates for, 20, 23

### Liver cancer

Death rates for, 12-13, 15  
Incidence of, 14, 21-22  
In alcohol abusers, 123  
Survival rates for, 283

### Lomustine, 274, 277

### Lung cancer

Asbestos-exposure related, 44-45, 48-55  
And smoking habits, 52  
Death rates for, 7, 12-13, 15, 17, 19, 51-52  
Incidence of, 7, 14, 16, 21, 149  
In people with diets high in vitamin A, 123

Metastasizing to the left atrium (case report), 40-43

Mortality rates for, 9

Rate of detection during screening for oral cancer, 266-267

Small cell carcinoma of the lung, 269-281

Biology and pathology of, 269-271

Clinical features of, 272-273

Cushing's syndrome, 272

Epidemiology of, 269

Treatment of, 273-278

Survival rates for, 20, 23, 273-277,

283, 287, 291

## Lymphomas

- Death rates for, 7, 15
- Incidence of, 7, 14, 22
- Mortality rates for, 9
- Survival rates for, 23
- Tribute to Henry S. Kaplan, 206-209

## M

### Macrobiotic diets (unproven methods), 60-63

### Malignant melanoma, 107-109

- Diagnosing level I (*in situ*), 107-109, 353-354 (letter)
- Incidence of, 107
- Insurability and level I (*in situ*) melanoma, 107-109, 353-354 (letter)
- And pregnancy (letter), 238-240
- Melanocytic dysplasia (letter), 353-354
- New Mexico Skin Cancer Project Survey, 107-109

### Mammography

- The continuing challenge of (opinion), 57-59
- ACR guidelines, 59
- Breast Cancer Detection Demonstration Projects (BCDDPs), 57-58
- Costs of, 58
- Warren, Stafford, 57
- Statistics (letter), 64

### Medical linear accelerator, 209

### Mesothelioma

- Asbestos-related, 45, 48, 51, 53-55

### Methotrexate, 274, 277

- And leucovorin rescue, 119

### Metochlorpropamide, 5

### Mitomycin C, 296

### Mormons

- Cancer mortality among, 128
- Cervical cancer in (letter), 302

### Multiple myeloma

- Death rates for, 15
- Incidence of, 14
- Survival rates for, 20

### Myocardial infarction

- And estrogen, 216

## N

### Nabilone

- Dosage for (correction), 147, 201
- To prevent nausea and vomiting from chemotherapy, 2-6, 147, 201

### Neurofibrosarcoma (case report), 295-298

- And the sign of Leser-Trélat (case report), 295-298
- Chemotherapy for, 296
- Radiation therapy for, 295

### Nitrogen mustard, 4

### Nolvadex, 346, 348

### Nursing

- Role in dealing with side effects of chemotherapy, 345
- Role in hospice, 204-205

### Nutrition and cancer, 121-126

- ACS recommendations, cause and prevention, 121-123
- ACS research, 126
- Cancer Prevention Studies I and II, 126
- Background, 124-125
- Dietary practice review, 123-124
- Artificial sweeteners, 124
- Cholesterol, 124
- Coffee, 124
- Cooking at high temperatures, 124
- Food additives, 124
- Selenium, 124
- Vitamin E, 124
- Migrating populations study, 125-126

## O

### Opinions, 57-59, 118-120, 210-231, 345-351

- Benefits of estrogen to the menopausal woman outweigh the risks of developing endometrial cancer, 210-231
- Con, 220-231
- Pro, 210-219

### The continuing challenge of mammography, 57-59

- The ethics of patient requests in experimental medicine, 118-120
- Is aggressive adjuvant chemotherapy the Halsted radical of the '80s?, 345-351

**Oral cancer**, 24–39, 262–268  
AJC staging of, 26–27  
Causes of, 24, 27  
Death rates for, 7, 15, 17–18  
Diagnosis of, 26  
Incidence of, 7, 14, 16, 21, 24–25  
In alcohol abusers who smoke cigarettes, 123  
Metastases in, 29  
Pathology of, 29, 33–34  
Radiation therapy for, 29  
Screening for, 262–268  
And smokeless tobacco, 242–246  
Of the salivary glands, 24–39  
Benign tumors, 29–38  
Malignant tumors, 30–38  
Radiation therapy for, 29  
Surgery for, 27–29, 37–38  
Treatment of, 27, 37–38, 81–82  
Tumor classification, 26–27  
Wartthin's tumor, 24, 30–34  
Survival rates for, 35–37, 262, 283–284, 291

**Osteosarcoma** (case report), 110–117  
Diagnosis of, 110–117

**Ovarian cancer**  
Death rates for, 7, 12, 15  
And estrogen, 226–227  
Incidence of, 7, 14, 21  
Mortality rates for, 9  
Survival rates for, 20, 23, 283, 287, 291

**Pheochromocytomas**, 86–92  
A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93–106  
And hypertension, 86, 89  
Use of arteriography to locate, 90  
Use of computed tomography to locate, 90  
Use of scintigraphy to locate, 86–91  
Use of ultrasonography to locate, 90

**Prednisone**, 346

**Pregnancy**  
And cancer (letter), 238–240  
And cervical cancer, 313

**Procarbazine**, 277

**Proctosigmoidoscopy**  
Benefits vs risks, 158–160  
For colorectal cancer detection, 132, 151, 153–155, 158–166, 333  
Examiners, knowledge and proficiency of, 161–163  
As follow-up for colorectal adenomas, 170–175  
Recommendations, 164  
Types of, 160

**Prostate cancer**

Age distribution by stage, 293  
Death rates for, 7, 13, 15, 17, 19  
Incidence of, 7, 14, 16, 21  
Mortality rates for, 9  
Sexual rehabilitation in, 69–70  
Survival rates for, 20, 23, 283–284, 287, 289, 291–293  
Treatment of, 82–84

## P

**Pancreatic cancer**  
Death rates for, 7, 12–13, 15, 17  
Incidence of, 7, 14, 16, 21  
Mortality rates for, 9  
Survival rates for, 283, 291

**Papanicolaou smear**, 307–308

**Papilloma virus**  
Transmissible agent of cervical cancer, 314–316

**Penile cancer**  
Correction (letter), 238  
Sexual rehabilitation in, 73

**Phenothiazines**, 5

## R

**Radiation therapy**, 75–85  
ACR Patterns of Care Study, 75–85  
Author's correction (letter), 303  
In cervical cancer, 80  
In colorectal cancer, 151, 154, 333–339  
In lung cancer, 275–277  
In neurofibrosarcoma (case report), 295  
Tribute to Henry S. Kaplan, 206–209

**Rectal cancer**

(See colorectal cancer)

## S

### **Salivary gland tumors, 24–39**

- AJC staging of, 26–27
- Causes of, 24, 27
- Radiation therapy for, 29
- Surgery for, 28–29, 37–38
- Survival rates for, 35–38
- Treatment of, 27–28, 37–38
- Types of, 29–38
  - Benign, 29–38
  - Malignant, 30–38

### **Scintigraphy**

- Detection of osteosarcoma with, 110–117
- Use in locating pheochromocytomas, 86–92

### **Screening**

- For breast cancer, 57, 59, 344
- Cancer Prevention Studies I and II, 126
- For cervical cancer, 306–308
- For colorectal cancer, 130–133, 134–147, 166, 333
- With the fecal occult blood test, 142–145
- Interrelationship of cancer control and clinical research in the community, 340–344
- For oral and oropharyngeal squamous carcinomas, 262–268

### **Secondary tumors**

- Left atrial (case report), 40–43

### **Selikoff, Irving, 45–47**

- Historical perspective of asbestos-related disease (classic), 45–47

### **Sexual rehabilitation, 66–74**

- Discussing the problem, 66–69
- In urologic cancer patients, 66–74, 354–355 (letter)

### **Skin cancer**

- Death rates for, 7, 14
- Incidence of, 7, 14, 21, 75
- Mortality rates for, 9
- New Mexico Skin Cancer Project Survey, 107–109
  - And malignant melanoma, 107–109
- Survival rates for, 23, 287

### **Small cell carcinoma, lung, 269–281**

### **Squamous cell cancer, 118–120**

- Chemotherapy in, 118–120

### **Statistics, cancer, 7–23**

(See also, specific sites)

### **ACS estimates of incidence and death, 7–23, 75**

- Death rates, 8, 22, 125
  - By geographic location, 17–19
  - By leading causes among children, 22
- By site and sex, 7, 12–13, 15

### **Incidence**

- By geographic location, 16
- By site and sex, 7, 14
- By site for children, 22
- By stage at diagnosis, 21

### **Mortality rates**

- By leading cancer sites, 9
- By leading causes, 8
- Leading causes by age and sex, 10–11

### **Survival rates**

- By site and race, 20
- Trends, by site and race, 23

### **Stomach cancer**

- Death rates for, 12–13, 15, 17, 19, 48, 52, 54
- Incidence of, 14, 16, 21, 54–55
  - In obese people, 122
  - In people with diets high in nitrate and nitrite, 123
  - In people with diets high in vitamin C, 123
- Mortality rates for, 9
- Survival rates for, 20, 23, 283–284, 287, 291

### **Streptozotocin, 4**

### **Surgery**

- In colorectal cancer, 168–170
- In lung cancer, 273–276
- In malignant melanoma (letter), 238–240
- In primary cardiac osteosarcoma, 112, 116
- In salivary gland tumors, 28–29, 37–38

### **Survival in untreated and treated cancer (classic), 282–294**

- Connecticut cancer register, 284–293
- Survival rates by site, 287–289, 291–293

### **Sympathetic nervous system cancer**

- Incidence of, 22

## T

### **Tamoxifen, 346, 348**

### **Teniposide, 278**

**Testicular cancer**  
Chemotherapy in, 3  
Death rates for, 15  
Incidence of, 14  
Mortality rates for, 9  
Sexual rehabilitation and, 72-73  
Survival rates for, 23  
Treatment of, 80-82

**Thyroid cancer**  
Death rates for, 15  
Incidence of, 14, 21  
Iodine-131 and thyroid suppression as treatment for (letter), 299-302  
Survival rates for, 23, 284, 287-289

**TNM cancer classification and staging system**, 304  
Request for suggestions on a unified system, 304

**Tobacco, smokeless**, 242-261  
A comparison of use in rural and urban teenagers, 248-261  
Age, sex, and clinical appearance, 249-251  
Anatomic location of lesions, 249-250, 252-255  
Classification of lesions, 251, 254  
Future research, 259-260  
Habituating effects of, 260-261  
Length of exposure, 250, 254, 258-260  
Level of dental care in study subjects, 257  
Symptomatology, race, and social habits, 250, 256  
Epidemiologic data from India, 243-244  
Increased promotion and use of, 242-243, 247-248  
Malignant transformation of leukoplakia, 245  
And oral cancer, 242-247

**Unproven methods of cancer management**, 60-63, 232-237  
Immuno-augmentative therapy, 232-237, 356 (letter)  
Macrobiotic diets, 60-63

**Untreated cancer, survival in**, 282-294

**Urinary cancer**  
Death rates for, 7, 13, 15  
Incidence of, 7, 14, 21  
Mortality rates for, 9  
Survival rates for, 20, 23

**Urologic cancer**, 66-74  
Sexual rehabilitation of patients with, 66-74, 354-355 (letter)  
Bladder cancer, 71-72  
Discussing the problem, 66-69  
Penile cancer, 73  
Prostate cancer, 69-70  
Testicular cancer, 72-73

**Urostomy appliance**  
Sexual rehabilitation and, 71

**Uterine cancer**  
Death rates for, 7, 12, 15, 17, 19  
Incidence of, 7, 14, 16, 21  
In obese people, 122  
Mortality rates for, 9  
Survival rates for, 20, 23, 287, 289, 293

## V

---

**Vinblastine**, 3

**Vincristine**, 274, 277, 296, 346

**Vindesine**, 278

**Viral agents**  
As causes of cervical cancer, 313-316

## U

---

**Ultrasonography**  
Use in locating pheochromocytomas, 90

## W

---

**Warren, Stafford**  
Mammography, 57

# **Author Index, 1984**

**Vol. 34, Nos. 1-6**

## **A**

Adams AB, 183-190  
Albain KS, 269-281  
Averette HE, 306-327

## **B**

Bachman LH, 238  
Bagshaw MA, 208-209  
Baker HW, 304  
Barnes CA, 353  
Barsa P, 262-268  
Beierwaltes WH, 86-92  
Bitran JD, 269-281  
Braunstein GD, 210-219  
Breslow DM, 191-201

## **C**

Caldronay RD, 40-43  
Churg J, 48-56  
Copp JE, 86-92  
Crane LA, 191-201  
Crespi M, 158-166  
Crowley LV, 356-357  
Cullen JW, 328-332  
Cutler SJ, 282-294

## **D**

DeCosse JJ, 357  
Diamond JJ, 75-85  
Dodd GD, 57-59  
Donegan WL, 240  
Durant JR, 2-6

## **E**

Elliott EC, 40-43  
Ellis FH, Jr., 127-128  
Enck RE, 340-344  
von Eschenbach AC, 66-74

## **F**

Fleisher M, 134-147, 352-353  
Fordham EW, 110-117  
Fränkel F, 93-106

## **G**

Ganz PA, 191-201  
Garfinkel L, 44-47, 64  
Gilbert I, 354-355  
Gilbertsen VA, 158-166  
Gnauck R, 134-147  
Golomb HM, 269-281  
Gonzalez J, 66-74  
Goren CC, 110-117  
Goulston K, 148-157  
Graney MJ, 333-339  
Greengor DH, 352  
Greene PE, 204-205  
Greenwald P, 328-332  
Greer RO, Jr., 248-261  
Griswold MH, 282-294

## **H**

Hammond EC, 48-56  
Hanks GE, 75-85  
Hawk JC, Jr., 238-239  
Henderson BE, 356  
Henkin RE, 300-301  
Hinson EJ, 333-339  
Hoffman PC, 269-281  
Hollob AI, 206-207  
Hunt RH, 148-157

## **J**

Jacobsen GA, 202-203

## **K**

Kern S, 302

Kopecky K, 299-300  
Kramer S, 75-85, 303  
Kushner R, 345-351

## L

---

Lambert R, 167-176  
Leiferman KM, 295-298  
Levene A, 239  
Lindenmuth JE, 248-261  
Luebke DC, 353  
Lyon JL, 302-303

## M

---

MacDonald N, 178-182  
MacLean CJ, 75-85  
Macrae FA, 134-147  
Mashberg A, 262-268  
McCall AR, 110-117  
McKenna RJ, 24-39  
Meyers JA, 64  
Micetich KC, 118-120  
Morrow CP, 220-231

## N

---

Nankin HR, 299  
Nelson JH, Jr., 306-327

## P

---

Park H-M, 299-300  
Poulson TC, 248-261  
Preston-Martin S, 356

## R

---

Rainey LC, 191-201  
Redman JC, 107-109, 353-354

Reinig JW, 127  
Richart RM, 306-327  
Rosenberg MS, 110-117  
Rozek S, 110-117  
Rubin J, 295-298

## S

---

Schneiderman H, 110-117  
Schover LR, 66-74, 355  
Selikoff IJ, 48-56  
Shapiro B, 86-92  
Sherlock P, 158-166  
Shimkin MB, 282-294  
Silverberg E, 7-23  
Sischy B, 333-339  
Sisson JC, 86-92  
Smalley SR, 295-298  
Smith DB, 66-74  
Sobin LH, 167-176, 304  
Squier CA, 242-247  
Stalder GA, 167-176  
Stroehlein JR, 148-157

## T

---

Thomasma DC, 118-120

## W

---

Wanebo HJ, 301-302  
Waye JD, 167-176  
Weisburger JH, 128  
Weissman GS, 158-166  
Winawer SJ, 130-133, 158-166

## Z

---

Zavernik JJ, 356

